Neoadjuvant hormonal therapy with bicalutamide 150 mg before radical treatment in patients with localized and locally advanced prostate cancer
https://doi.org/10.17650/1726-9776-2008-4-4-44-48
Abstract
Hormonal therapy of prostate cancer is the method of choice in patients who can not be treated radically. For patients with locally advanced renal cancer the monotherapy with bicalutamide can be used as an alternative to castration.
In our study we tried to determine the degree of decrease of prostate gland volume and level of prostate specific antigen in the serum after therapy with 150 mg of bicalutamide per day. Besides, we also attempted to clarify whether preoperative or pre-radiation hormonal therapy with bicalutamide in the dose of 150 mg per day increases the time interval to clinical progression.
After hormonal therapy we observed considerable decrease of level of prostate specific antigen in the serum. Mean volume of prostate gland also has significantly diminished in comparison to pretreatment state.
The results of our study have demonstrated that therapy with bicalutamide can be an alternative approach to maximal androgenic blockage. As well, it can be used in neoadjuvant setting as hormonal therapy before radical treatment in patients with localized and locally advanced prostate cancer.
About the Authors
A. D. Kaprin
Federal State Enterprise Russian Research Center of Roentgen-Radiology of Russian Medical Technologies
Russian Federation
Moscow
Russian Federation
Moscow
R. A. Gafanov
Federal State Enterprise Russian Research Center of Roentgen-Radiology of Russian Medical Technologies
Russian Federation
Moscow
Russian Federation
Moscow
M. Halil Farzat
Federal State Enterprise Russian Research Center of Roentgen-Radiology of Russian Medical Technologies
Russian Federation
Moscow
Russian Federation
Moscow
References
1. Давыдов М.И., Аксель Е.М. Злокачественные новообразования в России и странах СНГ в 2001 г. М., 2003.
2. Харченко В.П., Каприн А.Д., Гафанов Р.А. и др. Химиотерапия гормонорезистентного рака простаты. Тезисы I конгресса профессиональной ассоциации андрологов России. Кисловодск—Домбай, 2001. с. 35—6.
3. Huggins C., Hoges C.V. Studies on prostate cancer. The effect of castration. Cancer Res 1941;385—402.
4. Anderson J. Treatment of prostate cancer — the role of primary hormonotherapy. EAU Update Series 2003;1:32—9.
5. Dawson N.A. Intermittent androgen deprivation. Curr Oncol Rep 2000;2:409—16.
6. Neumann F. et al. Pharmacological basis for clinical use of antiandrogens. J Steroid Biochem 1983;19(1A):391—402.
7. Knuth U.A., Hano R., Nieschlag E. Effect of flutamide or cyproterone acetate on pituitary and testicular hormones in normal men. J Clin Endocrinol Metabol 1984;59(5):963—9.
8. Geller J., Vazka G., Fruchtman B. et al. The effect of cyproterone acetate on advanced carcinoma of the prostate. Surgery Gynecol Obstetrics 1968;127:748—58.
9. Smith R.B., Walsh P.C., Goodwin W.E. Cyproterone acetate in the treatment of advanced carcinoma of the prostate. J Urol 1973;110(1);106—8.
10. Altwein J.E., Jacobi G.H., Hohenfellner R. Estrogen versus cyproterone acetate in untreated inoperable carcinoma of the prostate: first results of an open, prospective, randomized study. Abstracts 3rd Congress of the European Association of Urology, Monte Carlo, 1978.
11. Jacobi G.H., Altwein J.E., Kurth K.H. et al. Treatment of advanced prostatic cancer with parenteral cyproterone acetate: a phase III randomized trial. Brit J Urol 1980;52:208—15.
12. Varenhorst E., Wallentin L., Risberg B. The effects of orchiectomy, estrogens and cyproterone acetate on the antithrombin III concentration in carcinoma of the prostate. Urol Res 1981;9:25—8.
13. Tunn U.W., Senge T., Jacobi G.H. Clinical experience with cyproterone acetate as monotherapy in inoperable carcinoma of the prostate. The therapy of advanced carcinoma of the prostate, Schering AG, Germany 1984; 67—75.
14. Pavone-Macaluso M., de Voogt H.J., Viggiano G. et al. Comparison of diethylstilbestrol, CPA and medroxy-progesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the Europ. Organisation for research and treatment of cancer. J Urol 1986; 136:624—31.
15. Schroder E.H., Whelan P., Kurth K.H. et al. A preliminary report on EORTC protocol 30892. E.H. Schroder (ed); Recent advances in prostate cancer and BPH., Proceedings of the PACIOU IV-Congress, 1996; Parthenon, N.Y., London 1996; 141—6.
16. Schulze R., Senge Th. Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogueinduced testosterone surge in patients with metastatic carcinoma of the prostate. J Urol 1990;144:934—41.
17. Waxman J., Williams G., Sandow J. et al. The clinical and endocrine assessment of three different antiandrogen regimens combined with a very long-acting gonadotrophin-releasing hormone analogue. Am J Clin Oncol 1988;11(Suppl 2):152—5.
Review
For citations:
Kaprin A.D., Gafanov R.A., Halil Farzat M. Neoadjuvant hormonal therapy with bicalutamide 150 mg before radical treatment in patients with localized and locally advanced prostate cancer. Cancer Urology. 2008;4(4):44-48. (In Russ.) https://doi.org/10.17650/1726-9776-2008-4-4-44-48
Views:
299
Email this article 